Bajaj Healthcare Ltd vs Corona Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Bajaj Healthcare Ltd is ₹ 274.95 as of 18 May 15:30 . The P/E Ratio of Bajaj Healthcare Ltd is 0 as of March 2023 .The P/E Ratio of Corona Remedies Ltd is 0 as of March 2023 . The Market Cap of Bajaj Healthcare Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Corona Remedies Ltd is ₹ 0 crore as of March 2023 . The revenue of Bajaj Healthcare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Corona Remedies Ltd for the Mar '26 is ₹ 357.48 crore as compare to the Dec '25 revenue of ₹ 344.68 crore. This represent the growth of 3.71% The ebitda of Bajaj Healthcare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Corona Remedies Ltd for the Mar '26 is ₹ 66.41 crore as compare to the Dec '25 ebitda of ₹ 66.32 crore. This represent the growth of 0.14% The net profit of Bajaj Healthcare Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 45.33 crore over 8 quarters. This represents a CAGR of 23.03% The Dividend Payout of Bajaj Healthcare Ltd changed from 4.57 % on March 2021 to 7.99 % on March 2025 . This represents a CAGR of 11.82% over 5 yearsThe Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 years .

About Bajaj Healthcare Ltd

Incorporated in 1993, Maharashtra-based Bajaj Healthcare Limited is one of India's large scale and vertically integrated pharmaceutical manufacturer for quality-conscious customers.
The Company is engaged in the manufacturing and exporting of Active Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals. Company commenced its operations in 1993 with a single unit at Tarapur.
It became a public company in 2005 and listed its shares in the Indian stock exchanges in 2016. With Headquartered in Thane, Company has established 3 API plants in Gujarat and Maharashtra.
It has 4 units for APIs/ intermediates and one unit for formulation, which are designed to meet the requirements of both advanced as well as emerging market opportunities.
In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility.

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

FAQs for the comparison of Bajaj Healthcare Ltd and Corona Remedies Ltd

Which company has a larger market capitalization, Bajaj Healthcare Ltd or Corona Remedies Ltd?

Market cap of Bajaj Healthcare Ltd is 925 Cr while Market cap of Corona Remedies Ltd is 11,137 Cr

What are the key factors driving the stock performance of Bajaj Healthcare Ltd and Corona Remedies Ltd?

The stock performance of Bajaj Healthcare Ltd and Corona Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bajaj Healthcare Ltd and Corona Remedies Ltd?

As of May 18, 2026, the Bajaj Healthcare Ltd stock price is INR ₹274.95. On the other hand, Corona Remedies Ltd stock price is INR ₹1821.1.

How do dividend payouts of Bajaj Healthcare Ltd and Corona Remedies Ltd compare?

To compare the dividend payouts of Bajaj Healthcare Ltd and Corona Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.